Project Grant R21CA317314
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $424K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $162,608 under the Cancer Treatment Research program (CFDA 93.395) on August 14, 2026. The award funds an exploratory research project characterizing how moderate-dose external radiotherapy enhances blood perfusion in hepatocellular carcinoma tumors, with the goal of optimizing combination strategies between ionizing radiation and perfusion-driven therapies. The research involves irradiating a...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $437,113 to Massachusetts Eye and Ear Infirmary on June 8, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop fluorescence lifetime imaging methods for quantifying in vivo PD-L1 target engagement in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitor monoclonal antibodies. The project addresses a...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Institutes of Health National Cancer Institute awarded $421,825 to The General Hospital Corporation (Massachusetts General Hospital) on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an improved fibrin-targeted radiopharmaceutical for gastric cancer treatment. The project addresses advanced gastric cancer, for which chemotherapy remains the standard treatment but nearly all patients eventually relapse or experience disease progression. The...
- This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $432,050 on August 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop peptide-MHC pseudotyped retroviral vectors for in vivo gene delivery to antigen-specific T cells as a novel cancer immunotherapy approach. The work addresses a gap in current cancer immunotherapies by combining attributes of CAR-T cell therapies with tumor-infiltrating lymphocyte and immune checkpoint blockade...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- The National Cancer Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $161,460 under the Cancer Research Manpower program (CFDA 93.398) on June 1, 2026, to develop quantitative predictive dosimetry for transarterial radioembolization (TARE) in hepatocellular carcinoma treatment. The funded research will design a novel quantitative TARE dosimetry framework capable of predicting realistic yttrium-90 dose distributions to tumor tissue while...
- The National Cancer Institute awarded the President and Fellows of Harvard College $604,102 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop bioprinted three-dimensional vascular cancer models that enable study of T cell trafficking, dendritic cell engagement, and tumor cell killing within human and murine tumor microenvironments. The recipient will use microporous embedded printing to fabricate in vitro models incorporating vascular conduits for...
- The National Cancer Institute awarded Massachusetts General Hospital $420,610 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate serial killing by CD8+ T cells using a novel "kiss-of-death" intercellular labeling platform. The award funds development and application of the kiss-of-death assay, a granzyme-activated, sortase-based intercellular labeling system that directly measures individual T-cell-to-tumor-cell cytolysis. The assay labels CD8+...